Anaphylaxis management: The essential role of adrenaline (epinephrine) auto-injectors. Should PHARMAC fund them in New Zealand?

New Zealand Medical Journal

Volumn 119, Issue 1233, 2006, Pages

  Fitzharris, Penny ^a   Empson, Marianne ^a   Ameratunga, Rohan ^a   Sinclair, Jan ^b   Crump, Vincent ^c   Steele, Richard ^d   Broom, Brian ^e,f  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^c Auckland Clinical Studies   (New Zealand)

^d WELLINGTON HOSPITAL   (New Zealand)

^e Arahura Health Centre   (New Zealand)

^f AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; VENOM; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ACCURACY; AMPOULE; ANAPHYLAXIS; ARTICLE; AUSTRALIA; CLINICAL TRIAL; DESENSITIZATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELF ADMINISTRATION; DRUG USE; FOOD ALLERGY; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HIGH RISK POPULATION; HUMAN; IDIOPATHIC DISEASE; NEEDLE; NEW ZEALAND; NONBIOLOGICAL MODEL; PHARMACY; SELF INJECTION; SYRINGE; UNSPECIFIED SIDE EFFECT; ADULT; CHILD; DRUG CONTROL; ECONOMICS; EMERGENCY HEALTH SERVICE; HEALTH CARE DELIVERY; INSTRUMENTATION; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; PUBLIC HEALTH;

ADRENERGIC BETA-AGONISTS; ADULT; ANAPHYLAXIS; CHILD; DRUG AND NARCOTIC CONTROL; DRUG DELIVERY SYSTEMS; EMERGENCY MEDICAL SERVICES; EPINEPHRINE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INJECTIONS, INTRAMUSCULAR; NATIONAL HEALTH PROGRAMS; NEW ZEALAND; SELF ADMINISTRATION;

EID: 33646560919     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol. 2005;115:584-91.
2. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;47:373-80.
3. Sheikh A, Alves B. Hospital admissions for acute anaphylaxis: time trend study. BMJ. 2000:320:1441.
4. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol. 2004;4:285-290.
5. Pumphrey RSH. Lessons for the management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy. 2000;30:1144-1150.
6. Bock SA, Munoz-Furlong A, Sampson HA, et al. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3.
7. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327:380-4.
8. Mullins RJ. Anaphylaxis: risk factors for recurrence Clin Exp Allergy. 2003;33:1033-40.
9. Ewan P, Clark A. Long term prospective observational study of the outcome of a management plan in patients with nut allergy referred to a regional allergy centre. Lancet. 2001;357:111-5.
10. Gold MS, Sainsbury R. First aid anaphylaxis management in children who were prescribed an adrenaline autoinjector device (EpiPen). J Allergy Clin Immunol. 2000;106:171-6.
11. Kemp SF, Lockey RF, Wolf BL, Lieberman P. Anaphylaxis: a review of 266 cases. Arch Intern Med. 1995;155:1749-54.
12. McLean-Tooke APC, Bethune CA, Fay AC, Spickett GP. Adrenaline in the treatment of anaphylaxis: what is the evidence? BMJ. 2003;327:1332-5.
13. Project Team of the Resuscitation Council (UK). The emergency medical treatment of anaphylactic reactions for first medical responders and for community nurses. Revised Jan 2002. Available online. URL: http://www.resus.org.uk/pages/reaction.htm Accessed May 2006.
14. Johnston SL, UnsworthJ, Gompels M. Adrenaline given outside the context of life threatening allergic reactions. BMJ. 2003;326:589-90.
15. Montanaro A, Bardana EJ Jr. The mechanisms, causes, and treatments of anaphylaxis. J Investig Allergol Clin Immunol. 2002;12:2-11.
16. Simons FE, Roberts JR, Gu X, Simons KJ. Epineprine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol. 1998;101:33-7.
17. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. 2001;108:871-3.
18. Simons FER, Chan ES, Gu X, Simons KJ. Epinephrine for the out-of-hospital (first aid) treatment of anaphylaxis in infants: is the ampule/syringe/needle method practical? J Allergy Clin Immunol. 2001;108:1040-4.
19. Hayman GR, Bansal JA, Bansal AS. Knowledge about using auto-injectable adrenaline: review of patients' case notes and interviews with general practitioners. BMJ. 2003;327:1328.
20. Avery NJ, King RM, Knight S, Hourihane JO'B. Assessment of quality of life in children with peanut allergy. Pediatr Allergy Immunol. 2003:14:378-82. Available online. URL: http://www.blackwell-synergy.com/ doi/abs/10.1034/j.1399-3038.2003.00072.x Accessed May 2006.
21. Hu W, Kemp A, Kerridge I. Making clinical decisions when the stakes are high and the evidence unclear. BMJ. 2004;329:852-4.
22. Hu W, Kerridge I, Kemp A. Risk, rationality, and responding to the uncertainty of childhood food anaphylaxis. Med Humanit. 2005;31:12-16.
23. Simons, FE. Lack of worldwide availability of epinephrine autoinjectors for outpatients at risk of anaphylaxis. Ann Allergy Asthma Immunol. 2005;94:534-8.